In This Issue
Cancer Discov November 1 2019 9 (11) 1469-1472; DOI:10.1158/2159-8290.CD-ITI9-11
Glutamate metabotropic receptor 4 regulates the expression of the inflammatory cytokine IL23 in mice, leading to a restriction of osteosarcoma development that can be therapeutically targeted.
Combination treatment with PD-1 and CLTA4 inhibitors both before and after bone-marrow transplant into lymphodepleted recipient mice increased antitumor efficacy over immune-checkpoint blockade or bone-marrow transplant alone in a γc-dependent manner.
Phosphorylation of MED1 by the cyclin-dependent kinase CDK7 leads to an interaction between MED1 and AR, and CDK7 inhibition causes tumor regression in a mouse model of castration-resistant prostate cancer.
The core circadian proteins BMAL1 and CLOCK are essential to the maintenance of glioblastoma stem cells, and genetic or pharmacologic inhibition of BMAL1 or CLOCK increased survival in a mouse model of glioblastoma.
A positive feedback loop involving the disintegrin metalloproteinase ADAMDEC1 maintains the stemness of recurrence-driving glioblastoma stem cells.
An in vivo CRISPR screen of LKB1 targets identified SIK1 and SIK3 as mediators of the tumor-suppressive effects of LKB1 in the lung.
Lack of activation of the AMPK-related kinases SIK1 and SIK3 may be responsible for the tumorigenic effect of LKB1 mutations in non–small cell lung cancer.